That's an interesting take on the value of CKD growacet. In the USA the number of CKD patients is approximately 6X's that of Alzheimer's/dementia patients. One more item to put in the mix, vascular dementia is about 65% of those that make up the total Alzheimer's/dementia patients.

Needless to say both of those markets are large, very large with little or no competition for the effects that ABL appears to have.

tada